Abstract

Disclosed are capped abellaite (NaPb2(CO3)2OH), hydrocerussite (2PbCO3—Pb(OH)2), lead (II) carbonate (PbCO3), lead (II) tungstate (PbWO4), bismuth oxide (Bi2O3), and combinations thereof nanoparticles that are dispersed within an aqueous gelling solution to produce stable gels and function as an injectable contrast agent for vascular imaging. The contrast agent has good radioopacity, is inexpensive to produce, and is safe to handle. This provides a new method to image the fine vasculature of biological systems.

IPC Classes  ?

• A61K 49/04 - X-ray contrast preparations
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

Disclosed are methods of monitoring the detachment of a biofilm from the surface of an object or rearrangement of the structure of the biofilm in response to shear stress and also methods of identifying compositions having biofilm detachment activity or evaluating the biofilm detachment efficacy of compositions.

IPC Classes  ?

• C12Q 1/18 - Testing for antimicrobial activity of a material
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

Systems, computer-implemented methods, and computer program products to facilitate end to end integration of dialogue history for spoken language understanding are provided. According to an embodiment, a system can comprise a processor that executes components stored in memory. The computer executable components comprise a conversation component that encodes speech-based content of an utterance and text-based content of the utterance into a uniform representation.

IPC Classes  ?

• G10L 19/00 - Speech or audio signal analysis-synthesis techniques for redundancy reduction, e.g. in vocodersCoding or decoding of speech or audio signals, using source filter models or psychoacoustic analysis
• G06F 40/126 - Character encoding
• G06N 3/045 - Combinations of networks
• G10L 15/00 - Speech recognition

Abstract

The instant disclosure provides engineered proteins, constructs for expressing the engineered proteins, and methods of using the engineered proteins and constructs for tethering a protein of interest to an RNA molecule.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/86 - Viral vectors
• G16B 20/30 - Detection of binding sites or motifs
• G16B 20/50 - Mutagenesis

Abstract

Disclosed are methods of monitoring the detachment of a biofilm from the surface of an object or rearrangement of the structure of the biofilm in response to shear stress and also methods of identifying compositions having biofilm detachment activity or evaluating the biofilm detachment efficacy of compositions.

IPC Classes  ?

• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses

Abstract

A dishwashing appliance includes a tub defining a wash chamber for receipt of articles for washing. A sump is a sump positioned at a bottom of the wash chamber for receiving fluid from the wash chamber. A circulation pump is connected to the sump. The dishwashing appliance also includes a mounting cable extending from the circulation pump. The circulation pump is suspended by the mounting cable.

IPC Classes  ?

• A47L 15/22 - Rotary spraying devices
• A47L 15/42 - Washing or rinsing machines for crockery or table-ware Details

Abstract

Methods are provided for treating lung cancer, and more particularly for treating pulmonary adenocarcinoma in a canine subject. The method may comprise assaying a biological sample from the canine subject, such as a tumor sample or a plasma sample, for a mutation in the HER2 gene. The mutation may include HER2 V659E, HER2 A664T, or HER2 K676E. If one or more of the mutations is present in the biological sample, the methods further include treating the canine subject by administering a therapeutically effective amount of an inhibitor of HER2. For example, a HER2 V659E may indicate increase sensitivity to a HER2 inhibitor. The HER2 inhibitor may include a small molecule HER2 inhibitor, such as trastuzumab, neratinib, lapatinib, erlotinib, and pertuzumab.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The current disclosure relates to methods, compositions and kits for detecting modified adenosine in a target RNA molecule. Aspects relate to a method for detecting modified adenosine in a target ribonucleic acid (RNA) comprising contacting the target RNA with an adenosine deaminase enzyme (adenosine deaminase, RNA-specific) to generate a target RNA with deaminated adenosines and sequencing the target RNA with deaminated adenosines; wherein the modified adenosine is detected when the nucleotide sequence includes adenosine within a m6A motif.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 35/76 - VirusesSubviral particlesBacteriophages

Abstract

Clostridium perfringens extracellular proteins to the mucosal membrane of the intestinal tract of a bird of the order Galliformes.

IPC Classes  ?

• A61K 39/08 - Clostridium, e.g. Clostridium tetani
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A method of detecting sub-surface voids in a sample comprises positioning a probe adjacent to a first point on the sample, emitting an ultrasonic wave from the probe towards the sample, moving the probe towards the sample, measuring a shear force amplitude of a reflection of the ultrasonic wave at the probe as the probe moves towards the sample, creating an approach curve by plotting the measured shear force amplitude of the reflection of the ultrasonic wave as a function of a distance between the probe and the sample, and determining whether a sub-surface void exists at the first point on the sample based on a slope of the approach curve.

IPC Classes  ?

• G01N 29/34 - Generating the ultrasonic, sonic or infrasonic waves
• G01N 29/04 - Analysing solids
• G01N 29/06 - Visualisation of the interior, e.g. acoustic microscopy

Abstract

The present invention concerns a method for culturing a plant, said method comprising a culture step wherein said plant is submitted to repeated thermal cycles, wherein, for each thermal cycle, cool temperature and warm temperature are alternately artificially applied to all or a part of said plant, over a period shorter than natural seasons. The present invention also concerns a method for producing natural rubber from latex-producing plants, said method comprising the steps of (a) culturing the latex- producing plant by implementing the method of culture of the invention, (b) harvesting part or all of root part of said plant, and (c) extracting natural rubber from the root part harvested at step b).

IPC Classes  ?

• A01G 7/00 - Botany in general
• A01G 22/00 - Cultivation of specific crops or plants not otherwise provided for

Abstract

The present invention concerns a method for culturing a plant, said method comprising a culture step wherein said plant is submitted to repeated thermal cycles, wherein, for each thermal cycle, cool temperature and warm temperature are alternately artificially applied to all or a part of said plant, over a period shorter than natural seasons. The present invention concerns a method for culturing a plant, said method comprising a culture step wherein said plant is submitted to repeated thermal cycles, wherein, for each thermal cycle, cool temperature and warm temperature are alternately artificially applied to all or a part of said plant, over a period shorter than natural seasons. The present invention also concerns a method for producing natural rubber from latex-producing plants, said method comprising the steps of (a) culturing the latex-producing plant by implementing the method of culture of the invention, (b) harvesting part or all of root part of said plant, and (c) extracting natural rubber from the root part harvested at step b).

IPC Classes  ?

• C08C 1/04 - PurifyingDeproteinising
• C08H 8/00 - Macromolecular compounds derived from lignocellulosic materials
• A01H 6/00 - Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy

Abstract

The present invention concerns a method for culturing a plant, said method comprising a culture step wherein said plant is submitted to repeated thermal cycles, wherein, for each thermal cycle, cool temperature and warm temperature are alternately artificially applied to all or a part of said plant, over a period shorter than natural seasons. The present invention also concerns a method for producing natural rubber from latex-producing plants, said method comprising the steps of (a) culturing the latex- producing plant by implementing the method of culture of the invention, (b) harvesting part or all of root part of said plant, and (c) extracting natural rubber from the root part harvested at step b).

IPC Classes  ?

• A01G 7/00 - Botany in general
• A01G 22/00 - Cultivation of specific crops or plants not otherwise provided for

Abstract

The present application provides pyridine, pyrimidine, and pyrazine derivatives that activate excitatory amino acid transporter 2 (EAAT2), and methods of using the derivatives for treating or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• C07D 239/42 - One nitrogen atom
• C07D 241/18 - Oxygen or sulfur atoms
• C07D 241/20 - Nitrogen atoms
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

An electronics system may include a substrate, an electronic device bonded to the substrate, a plurality of photoluminescent particles disposed on the electronic device, an illuminator, a sensor, and a control module. The illuminator can illuminate the electronic device. The sensor can capture a first set of positions of the photoluminescent particles on the electronic device when the electronic device is not operating under a load and a second set of positions of the photoluminescent particles when the electronic device is operating under a load. The control module can determine thermomechanical stress on the electronic device based at least in part on a difference between the first set of positions and the second set of positions.

IPC Classes  ?

• G06T 7/00 - Image analysis
• H01L 21/67 - Apparatus specially adapted for handling semiconductor or electric solid state devices during manufacture or treatment thereofApparatus specially adapted for handling wafers during manufacture or treatment of semiconductor or electric solid state devices or components
• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• G01L 1/16 - Measuring force or stress, in general using properties of piezoelectric devices
• G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis

Abstract

Formulations for chemoprevention of oral cancer and precancerous lesions, and for methods for preparing the formulations are described.

IPC Classes  ?

• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/07 - Retinol compounds, e.g. vitamin A
• A61K 9/70 - Web, sheet or filament bases
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Abstract

The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.

IPC Classes  ?

• A61K 35/768 - Oncolytic viruses not provided for in groups
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• C07K 14/54 - Interleukins [IL]
• C12N 15/86 - Viral vectors
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

Methods are provided for treating lung cancer, and more particularly for treating pulmonary adenocarcinoma in a canine subject. The method may comprise assaying a biological sample from the canine subject, such as a tumor sample or a plasma sample, for a mutation in the HER2 gene. The mutation may include HER2 V659E, HER2 A664T, or HER2 K676E. If one or more of the mutations is present in the biological sample, the methods further include treating the canine subject by administering a therapeutically effective amount of an inhibitor of HER2. For example, a HER2 V659E may indicate increase sensitivity to a HER2 inhibitor. The HER2 inhibitor may include a small molecule HER2 inhibitor, such as trastuzumab, neratinib, lapatinib, erlotinib, and pertuzumab.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6844 - Nucleic acid amplification reactions
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to maresins, preferably maresin-1, for use in the treatment of CNS injuries preferably selected from spinal cord injury and traumatic brain injury.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 8/36 - Carboxylic acidsSalts or anhydrides thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A23L 33/12 - Fatty acids or derivatives thereof
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof

Abstract

This invention features new compositions and methods that are useful in treating a host with a Gram-negative bacterial infection. Combination therapies comprising an aminocoumarin compound and a polymyxin compound are disclosed, including certain combinations that exhibit synergistic effects. Furthermore, aminocoumarin compounds are described having altered inhibition of DNA gyrase in Gram-negative bacteria and/or the ability to target the transport proteins responsible for assembling lipopolysaccharide in the outer membrane of Gram-negative bacteria.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 38/12 - Cyclic peptides
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61P 31/04 - Antibacterial agents

Abstract

The current disclosure relates to methods, compositions and kits for detecting modified adenosine in a target RNA molecule. Aspects relate to a method for detecting modified adenosine in a target ribonucleic acid (RNA) comprising contacting the target RNA with an adenosine deaminase enzyme (adenosine deaminase, RNA-specific) to generate a target RNA with deaminated adenosines and sequencing the target RNA with deaminated adenosines; wherein the modified adenosine is detected when the nucleotide sequence includes adenosine within a m6A motif.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C12N 7/02 - Recovery or purification
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units

Abstract

A method inhibiting and/or reducing β-amyloid accumulation and/or Tau aggregation in a subject in need thereof includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention provides for a proteomic approach for identification of specific bacterial protein profiles that may be used in the development of methods for the diagnosis of bacterial chronic sinusitis. The invention provides for methods for determining the presence of pathogenic bacteria in the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria. The invention also provides for methods of diagnosing a bacterial infection of the upper respiratory tract of a subject using protein profiles of a pathogenic bacteria. In addition, the invention provides for devices, immunoassays and kits for identifying pathogenic bacteria in the upper respiratory tract.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/07 - Bacillus
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The disclosure relates to PRMT5 inhibitors, including optionally substituted N-alkyl-9H-carbazole analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation and benign hematologic diseases using the compounds and compositions.

IPC Classes  ?

• C07D 209/82 - CarbazolesHydrogenated carbazoles
• C07D 209/86 - CarbazolesHydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
• C07D 209/88 - CarbazolesHydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Abstract

This disclosure provides miRNA/mRNA pairs that can be used to increase the efficacy of T cells or to down-modulate T cell efficacy and restore equilibrium.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Pyradizine derivatives that activity the excitatory amino acid transporter 2 (EAAT2) of the formula: and methods of use thereof for treating or preventing diseases, disorders, and conditions with glutamate toxicity.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 237/20 - Nitrogen atoms
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 35/00 - Antineoplastic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to maresins, preferably maresin-1, for use in the treatment of CNS injuries preferably selected from spinal cord injury and traumatic brain injury.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
• A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate

Abstract

The present invention relates to maresins, preferably maresin-1, for use in the treatment of CNS injuries preferably selected from spinal cord injury and traumatic brain injury.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
• A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate

Abstract

The present application provides pyridine, pyrimidine, and pyrazine derivatives that activate excitatory amino acid transporter 2 (EAAT2), and methods of using the derivatives for treating or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.

IPC Classes  ?

• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The invention provides for a proteomic approach for identification of specific bacterial protein profiles that may be used in the development of methods for the diagnosis of bacterial chronic sinusitis. The invention provides for methods for determining the presence of pathogenic bacteria in the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria. The invention also provides for methods of diagnosing a bacterial infection of the upper respiratory tract of a subject using protein profiles of a pathogenic bacteria. In addition, the invention provides for devices, immunoassays and kits for identifying pathogenic bacteria in the upper respiratory tract.

IPC Classes  ?

• A61K 39/102 - PasteurellaHaemophilus
• A61K 39/02 - Bacterial antigens
• A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

A Quaternary Mg—Zn—Ca-based alloy and a heat treatment process for producing bioresorbable bone fixation implants are described thereof. The mechanical and biocorrosion properties of the fabricated Mg-based alloy were improved by combining careful selection of the alloy's chemical composition and subsequent post-shaping process (heat treatments). Heat treatment process is more privileged especially after fabricating the part into its final shape such as in additive manufacturing (3D-printing) and powder metallurgy. In this way, it is possible to produce biocompatible, strong and less corrosive patient-specific bone fixation hardware. Also, such heat-treated Mg—Zn—Ca-based parts can be further coated with various types of biocompatible ceramic coatings for slower and more tailored biocorrosion rates.

IPC Classes  ?

• A61L 31/02 - Inorganic materials
• A61L 31/14 - Materials characterised by their function or physical properties
• C22F 1/06 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of magnesium or alloys based thereon
• C22C 23/04 - Alloys based on magnesium with zinc or cadmium as the next major constituent

Abstract

A method inhibiting and/or reducing .beta.-amyloid accumulation and/or Tau aggregation in a subject in need thereof includesadministering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases .

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/46 - Hydrolases (3)

Abstract

A method inhibiting and/or reducing β-amyloid accumulation and/or Tau aggregation in a subject in need thereof includesadministering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/46 - Hydrolases (3)

Abstract

The present invention relates to an integrated hybrid dental implant, and more particularly, to an integrated hybrid dental implant in which an opening portion formed at a screw body to enable a drug to be injected into an implantation site of the implant, and the mechanical stability is excellent despite the presence of the opening portion. The integrated hybrid dental implant according to the present invention enables a drug to be supplied to the area around the implantation site so as to induce bone regeneration into the implant after the implant has been placed at a bone-deficient site, has an additional mechanical strength when bone grows into the side openings and hollow inner channel, and allows the screw body to be integrally formed with the prosthesis section (i.e., one piece) to exhibit more excellent mechanical strength so that the implant can be useful as a dental implant.

IPC Classes  ?

• A61C 8/00 - Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereonDental implantsImplanting tools
• A61C 8/02 - Means for transfixation of natural teeth
• A61C 19/06 - Implements for therapeutic treatment
• A61C 13/225 - Fastening prostheses in the mouth

Abstract

Method and processes for synthesizing single-wall carbon nanotubes is provided. A carbon precursor gas is contacted with metal catalysts deposited on a support material. The metal catalysts are preferably nanoparticles having diameters less than about 50 nm. The reaction temperature is selected such that it is near the eutectic point of the mixture of metal catalyst particles and carbon.

IPC Classes  ?

• D01F 9/12 - Carbon filamentsApparatus specially adapted for the manufacture thereof
• C01B 32/162 - Preparation characterised by catalysts
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• D01F 9/127 - Carbon filamentsApparatus specially adapted for the manufacture thereof by thermal decomposition of hydrocarbon gases or vapours

Abstract

m) of from 1.0 to 2.0; and contains less than 1% w/w of poly(maleic anhydride-co-propylene oxide) polymer chains particularly. PPF polymers are non-toxic, degradable, and resorbable and can be used in tissue scaffolds and medical devices that are implanted within a living organism.

IPC Classes  ?

• C08G 63/78 - Preparation processes
• C08G 63/52 - Polycarboxylic acids or polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
• C08G 63/90 - PurificationDrying
• A61L 27/56 - Porous or cellular materials
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• C08L 67/06 - Unsaturated polyesters
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

Pyridazine derivatives that activate the excitatory amino acid transporter 2 (EAAT2), and methods of use thereof for treating or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

The present invention is directed to a method of isolating fractions of anthocyanin molecules from anthocyanin-containing vegetable and fruit juices and extracts, or combinations thereof, at a select pH based on differences in polarity of the anthocyanin molecules in the anthocyanin-containing vegetable and fruit juices and extracts.

IPC Classes  ?

• C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
• C09B 61/00 - Dyes of natural origin prepared from natural sources
• A23L 2/04 - Extraction of juices
• A23L 2/58 - Colouring agents
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• A23L 5/43 - Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives
• B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution

Abstract

The invention provides for a proteomic approach for identification of specific bacterial protein profiles that may be used in the development of methods for the diagnosis of bacterial chronic sinusitis. The invention provides for methods for determining the presence of pathogenic bacteria in the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria. The invention also provides for methods of diagnosing a bacterial infection of the upper respiratory tract of a subject using protein profiles of a pathogenic bacteria. In addition, the invention provides for devices, immunoassays and kits for identifying pathogenic bacteria in the upper respiratory tract.

IPC Classes  ?

• A61K 39/102 - PasteurellaHaemophilus
• A61K 39/02 - Bacterial antigens
• A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The present invention relates to an integrated dental hybrid implant and, more specifically, to an integrated dental hybrid implant having an opening formed on a screw body such that a drug can be injected at the implant site of the implant, and exhibiting excellent implant mechanical stability despite the presence of the opening. The integrated dental hybrid implant according to the present invention enables a drug to be supplied to the area around an implant site so as to induce bone generation inside the implant after the implant has been implanted at a bone-deficient site, has excellent implant mechanical strength despite the presence of the opening, and has more excellent mechanical strength by being integrated with a prosthesis part such that the implant can be useful as a dental implant.

IPC Classes  ?

• A61C 8/00 - Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereonDental implantsImplanting tools
• A61C 13/00 - Dental prosthesesMaking same

Abstract

A system for converting fuel is provided and includes a first reactor comprising a plurality of ceramic composite particles, the ceramic composite particles comprising at least one metal oxide disposed on a support, wherein the first reactor is configured to reduce the at least one metal oxide with a fuel to produce a reduced metal or a reduced metal oxide; a second and reactor configured to oxidize at least a portion of the reduced metal or reduced metal oxide from the said first reactor to produce a metal oxide intermediate; a source of air; and a third reactor communicating with said source of air and configured to regenerate the at least one metal oxide from the remaining portion of the solids discharged from the said first reactor and the solids discharged from the said second reactor for by oxidizing the metal oxide intermediate.

IPC Classes  ?

• B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
• B01J 19/24 - Stationary reactors without moving elements inside
• C01B 3/02 - Production of hydrogen or of gaseous mixtures containing hydrogen
• C01B 3/34 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents
• C10J 3/12 - Continuous processes using solid heat-carriers
• C10J 3/46 - Gasification of granular or pulverulent fuels in suspension
• C10J 3/48 - ApparatusPlants
• C10J 3/72 - Other features
• F23C 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

An apparatus and device for repetitive use in automotive testing is provided. The apparatus includes a frame dimensioned in the same shape as a bicycle frame. The frame includes a first support beam and a plurality of second support beams. The apparatus further includes an elastic member elastically coupling each of the plurality of second support beams to the first support beam so as to allow the frame to separate when impacted and be easily reassembled for further testing. The device includes a disk having a first radar transparent layer opposite a second radar transparent layer and a reflective film disposed between the first radar transparent layer and the second radar transparent layer. The reflective film has a radar cross section pattern similar to that of an actual bicycle wheel when seen by automotive radar.

IPC Classes  ?

• G01M 17/007 - Wheeled or endless-tracked vehicles
• H01Q 15/14 - Reflecting surfacesEquivalent structures
• G01S 13/00 - Systems using the reflection or reradiation of radio waves, e.g. radar systemsAnalogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
• B62H 3/06 - Separate supports or holders for parking or storing cycles involving forked supports or brackets for holding a wheel collapsible
• G01S 13/93 - Radar or analogous systems, specially adapted for specific applications for anti-collision purposes
• G01S 7/40 - Means for monitoring or calibrating

Abstract

The present invention provides a low molecular mass PPF polymer (and related methods) that is suitable for 3D printing and other polymer device fabrication modalities and can be made inexpensively in commercially reasonable quantities. These novel low molecular mass PPF polymers have a low molecular mass distribution (Ðm) and a wide variety of potential uses, particularly as a component in resins for 3D printing of medical devices. The ability to produce low Ðm PPF creates a new opportunity for reliable GMP production of PPF. It provides low cost synthesis and scalability of synthesis, blending of well-defined mass and viscosity PPF, and reduced reliance on solvents or heat to (a) achieve mixing of 3D printable resins or (b) and flowability during 3D printing. These PPF polymers are non-toxic, degradable, and resorbable and can be used in tissue scaffolds and medical devices that are implanted within a living organism.

IPC Classes  ?

• C08G 63/52 - Polycarboxylic acids or polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
• B29C 64/10 - Processes of additive manufacturing
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/58 - Materials at least partially resorbable by the body

Abstract

The present invention provides a low molecular mass PPF polymer (and related methods) that is suitable for 3D printing and other polymer device fabrication modalities and can be made inexpensively in commercially reasonable quantities. These novel low molecular mass PPF polymers have a low molecular mass distribution (Đm) and a wide variety of potential uses, particularly as a component in resins for 3D printing of medical devices. The ability to produce low Đm PPF creates a new opportunity for reliable GMP production of PPF. It provides low cost synthesis and scalability of synthesis, blending of well-defined mass and viscosity PPF, and reduced reliance on solvents or heat to (a) achieve mixing of 3D printable resins or (b) and flowability during 3D printing. These PPF polymers are non-toxic, degradable, and resorbable and can be used in tissue scaffolds and medical devices that are implanted within a living organism.

IPC Classes  ?

• C08G 63/52 - Polycarboxylic acids or polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• B29C 67/00 - Shaping techniques not covered by groups , or
• C08G 63/78 - Preparation processes
• C08G 63/90 - PurificationDrying

Abstract

Chimeric fusion proteins and polynucleotides encoding the chimeric fusion proteins are provided for the treatment of proliferative disorders, automimmune diseases and alloimmune responses. The chimeric fusion proteins comprise a CD24 extracellular domain, an EBV-induced 3 (EBB) polypeptide subunit, and a p28 IL-27 polypeptide subunit, wherein the EBB polypeptide and the p28 IL-27 polypeptide subunit are covalently joined by a flexible peptide linker.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/20 - Interleukins

Abstract

A direct-electrochemical-oxidation fuel cell for generating electrical energy includes a cathode provided with an electrochemical-reduction catalyst that promotes formation of oxygen ions from an oxygen-containing source at the cathode, a solid-state reduced metal, a solid-state anode provided with an electrochemical-oxidation catalyst that promotes direct electrochemical oxidation of the solid-state reduced metal in the presence of the oxygen ions to produce electrical energy, and an electrolyte disposed to transmit the oxygen ions from the cathode to the solid-state anode. A method of operating a solid oxide fuel cell includes providing a direct-electrochemical-oxidation fuel cell comprising a solid-state reduced metal, oxidizing the solid-state reduced metal in the presence of oxygen ions through direct-electrochemical-oxidation to obtain a solid-state reducible metal oxide, and reducing the solid-state reducible metal oxide to obtain the solid-state reduced metal.

IPC Classes  ?

• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
• H01M 8/22 - Fuel cells in which the fuel is based on materials comprising carbon or oxygen or hydrogen and other elementsFuel cells in which the fuel is based on materials comprising only elements other than carbon, oxygen or hydrogen
• H01M 8/1246 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides
• H01M 8/06 - Combination of fuel cells with means for production of reactants or for treatment of residues
• H01M 8/124 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte
• H01M 4/88 - Processes of manufacture
• H01M 4/90 - Selection of catalytic material

Abstract

The present invention is directed to a method of isolating fractions of anthocyanin molecules from anthocyanin-containing vegetable and fruit juices and extracts, or combinations thereof, at a select pH based on differences in polarity of the anthocyanin molecules in the anthocyanin-containing vegetable and fruit juices and extracts.

IPC Classes  ?

• C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
• C09B 61/00 - Dyes of natural origin prepared from natural sources
• A23L 2/04 - Extraction of juices
• A23L 2/58 - Colouring agents
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion

Abstract

A strain-hardenable stainless steel alloy includes hard secondary phases dispersed in an austenitic primary phase, the alloy including 0.3-0.6% nitrogen by weight.

IPC Classes  ?

• C22C 38/44 - Ferrous alloys, e.g. steel alloys containing chromium with nickel with molybdenum or tungsten
• C22C 38/58 - Ferrous alloys, e.g. steel alloys containing chromium with nickel with more than 1.5% by weight of manganese
• C22C 38/34 - Ferrous alloys, e.g. steel alloys containing chromium with more than 1.5% by weight of silicon
• C21D 9/00 - Heat treatment, e.g. annealing, hardening, quenching or tempering, adapted for particular articlesFurnaces therefor
• C21D 1/18 - HardeningQuenching with or without subsequent tempering
• B22F 3/15 - Hot isostatic pressing
• B22F 7/08 - Manufacture of composite layers, workpieces, or articles, comprising metallic powder, by sintering the powder, with or without compacting of composite workpieces or articles from parts, e.g. to form tipped tools with one or more parts not made from powder
• B32B 15/01 - Layered products essentially comprising metal all layers being exclusively metallic
• B32B 15/18 - Layered products essentially comprising metal comprising iron or steel
• C21D 6/00 - Heat treatment of ferrous alloys
• C22C 38/04 - Ferrous alloys, e.g. steel alloys containing manganese
• C22C 38/02 - Ferrous alloys, e.g. steel alloys containing silicon
• C22C 38/00 - Ferrous alloys, e.g. steel alloys
• F16K 25/00 - Details relating to contact between valve members and seats
• C22C 33/02 - Making ferrous alloys by powder metallurgy
• C21D 1/26 - Methods of annealing
• B22F 3/24 - After-treatment of workpieces or articles

Abstract

A strain-hardenable stainless steel alloy includes hard secondary phases dispersed in an austenitic primary phase, the alloy including 0.3-0.6% nitrogen by weight.

IPC Classes  ?

• C22C 38/00 - Ferrous alloys, e.g. steel alloys
• C22C 38/58 - Ferrous alloys, e.g. steel alloys containing chromium with nickel with more than 1.5% by weight of manganese
• B22F 7/02 - Manufacture of composite layers, workpieces, or articles, comprising metallic powder, by sintering the powder, with or without compacting of composite layers
• B22F 3/15 - Hot isostatic pressing

Abstract

Disclosed herein are superconducting wires. The superconducting wires can comprise a metallic matrix and at least one continuous subelement embedded in the matrix. Each subelement can comprise a non-superconducting core, a superconducting layer coaxially disposed around the non-superconducting core, and a barrier layer coaxially disposed around the superconducting layer. The superconducting layer can comprise a plurality of Nb3Sn grains stabilized by metal oxide particulates disposed therein. The Nb3Sn grains can have an average grain size of from 5 nm to 90 nm (for example, from 15 nm to 30 nm). The superconducting wire can have a high-field critical current density (Jc) of at least 5,000 A/mm2 at a temperature of 4.2 K in a magnetic field of 12 T. Also described are superconducting wire precursors that can be heat treated to prepare superconducting wires, as well as methods of making superconducting wires.

IPC Classes  ?

• C04B 35/45 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on copper oxide or solid solutions thereof with other oxides

Abstract

A new and distinct cultivar of Azalea plant named ‘STEWARD’, characterized by its globe to broad columnar plant form; freely branching habit; terminal truss flower arrangement; pure white hose-in-hose flowers with some yellow-green flecking in the throat of the petals; green-yellow flower buds; and hardiness in USDA zone 6a.

IPC Classes  ?

• A01H 5/02 - Flowers

Abstract

Myocobacteria tuberculosis.

IPC Classes  ?

• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

An artificial skin for use on a radar mannequin exposed to electromagnetic radiation having a predetermined frequency and a radar mannequin having the artificial skin are provided. The artificial skin and the radar mannequin with the artificial skin are configured to produce a radar cross section that closely approximates the radar cross section of a human. The artificial skin includes a conductive layer of material and a shielding layer of material. The conductive layer and the shielding layer are configured to reflect electromagnetic radiation at a level of an electromagnetic response of human skin exposed to the electromagnetic radiation. The shielding layer also electromagnetically shields an inside surface of the artificial skin from electromagnetic radiation.

IPC Classes  ?

• B32B 7/02 - Physical, chemical or physicochemical properties
• B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
• B32B 33/00 - Layered products characterised by particular properties or particular surface features, e.g. particular surface coatingsLayered products designed for particular purposes not covered by another single class
• H05K 9/00 - Screening of apparatus or components against electric or magnetic fields

Abstract

An artificial skin for use on a radar mannequin exposed to electromagnetic radiation having a predetermined frequency and a radar mannequin having the artificial skin are provided. The artificial skin and the radar mannequin with the artificial skin are configured to produce a radar cross section that closely approximates the radar cross section of a human. The artificial skin includes a conductive layer of material and a shielding layer of material. The conductive layer and the shielding layer are configured to reflect electromagnetic radiation at a level of an electromagnetic response of human skin exposed to the electromagnetic radiation. The shielding layer also electromagnetically shields an inside surface of the artificial skin from electromagnetic radiation.

IPC Classes  ?

• H01Q 15/14 - Reflecting surfacesEquivalent structures
• G01S 7/40 - Means for monitoring or calibrating
• H01Q 1/52 - Means for reducing coupling between antennas Means for reducing coupling between an antenna and another structure
• H01Q 15/00 - Devices for reflection, refraction, diffraction or polarisation of waves radiated from an antenna, e.g. quasi-optical devices
• G01S 7/00 - Details of systems according to groups , ,

Abstract

Compositions comprising therapeutic oligonucleotide compounds that target the expression of genes associated with tumorigenesis or cell transformation are provided. Methods are described to manipulate and treat the oncogenic deregulation of the TP53-associated apoptosis pathway. Markers for acute myeloid leukemia (AML) and uses thereof are described.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Data is received characterizing a result of a first visual sensitivity test assessing capacity to detect spatial form across one or more different target sizes, and different contrasts. Using the received data, one or more first parameters defining a first estimated visual sensitivity for a first range of contrasts and a second range of spatial frequencies is determined. One or more second parameters defining a second estimated visual sensitivity for a third range of contrasts and a fourth range of spatial frequencies is determined using the one or more first parameters and a statistical inference by at least presenting a first visual stimulus, receiving a response, and determining a second visual stimulus based at least on the response and at least a rule. The one or more second parameters is provided. Related apparatus, systems, techniques and articles are also described.

IPC Classes  ?

• A61B 3/02 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient
• A61B 3/06 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing light sensitivity, e.g. adaptationSubjective types, i.e. testing apparatus requiring the active assistance of the patient for testing colour vision
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors

Abstract

Described herein is the discovery that miR-21 targets and down-regulates the core mismatch repair (MMR) recognition protein complex hMSH2 and hMSH6. Anti-sense miR-21 is therefore proven as therapeutic herein. Therefore, compositions, kits, therapies and other methods, including methods of treatment/amelioration of symptoms, are disclosed herein.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A system for converting fuel is provided and includes a first reactor comprising a plurality of ceramic composite particles, the ceramic composite particles comprising at least one metal oxide disposed on a support, wherein the first reactor is configured to reduce the at least one metal oxide with a fuel to produce a reduced metal or a reduced metal oxide; a second reactor configured to oxidize at least a portion of the reduced metal or reduced metal oxide from the said first reactor to produce a metal oxide intermediate; a source of air; and a third reactor communicating with said source of air and configured to regenerate the at least one metal oxide from the remaining portion of the solids discharged from the said first reactor and the solids discharged from the said second reactor by oxidizing the metal oxide intermediate.

IPC Classes  ?

• B01J 19/30 - Loose or shaped packing elements, e.g. Raschig rings or Berl saddles, for pouring into the apparatus for mass or heat transfer
• C01B 3/34 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents
• C10J 3/12 - Continuous processes using solid heat-carriers
• C10J 3/46 - Gasification of granular or pulverulent fuels in suspension
• C10J 3/72 - Other features
• F23C 99/00 - Subject matter not provided for in other groups of this subclass
• C01B 3/02 - Production of hydrogen or of gaseous mixtures containing hydrogen
• C01B 3/32 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air
• C10J 3/02 - Fixed-bed gasification of lump fuel
• C10J 3/06 - Continuous processes

Abstract

A method and apparatus for producing lithium iron arsenic superconductor materials. An example of the method comprises providing at least one cathode comprised of iron arsenic, providing at least one anode comprised of a chemically inert material, placing the at least one cathode and at least one anode into an electrolyte comprised of molten lithium chloride and/or lithium bromide, and applying a voltage such that electrical current flows between the at least one anode and the at least one cathode.

IPC Classes  ?

• C25D 3/66 - ElectroplatingBaths therefor from melts
• C25D 9/04 - Electrolytic coating other than with metals with inorganic materials
• C25D 11/06 - Anodisation of aluminium or alloys based thereon characterised by the electrolytes used

Abstract

Indolyl or indolinyl compounds of formula (I): 6, are defined herein. Also disclosed is a method for treating cancer with these compounds.

IPC Classes  ?

• C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07D 209/12 - Radicals substituted by oxygen atoms
• C07D 209/40 - Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
• C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Abstract

The present invention provides materials and methods related to modulation of mismatch repair and genomic stability by miR-155.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

E. ewingii.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/29 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Richettsiales (O)
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The invention provides for a proteomic approach for identification of specific bacterial protein profiles that may be used in the development of methods for the diagnosis of bacterial chronic sinusitis. The invention provides for methods for determining the presence of pathogenic bacteria in the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria. The invention also provides for methods of diagnosing a bacterial infection of the upper respiratory tract of a subject using protein profiles of a pathogenic bacteria. In addition, the invention provides for devices, immunoassays and kits for identifying pathogenic bacteria in the upper respiratory tract.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

A fluid container spray device having a trigger lock mechanism with trigger tabs extending outwardly from the trigger and cleats extending inwardly from a moveable shroud. The cleats obstruct the tabs when the shroud is in a trigger lock position. A lever extending from beneath the shroud can be depressed, thereby moving the shroud from the trigger lock position to a trigger release position. The movement of the shroud to the trigger release position moves the connected cleats from their obstructive position to a position out of the trigger tabs' path of movement, thereby permitting use of the trigger to pump fluid from the container. The shroud is biased toward the trigger lock position. Thus, release of the container by the user restores the locked configuration, thereby preventing use by children.

IPC Classes  ?

• B05B 11/00 - Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use

Abstract

The present invention is directed to natural blue anthocyanin-containing colorants comprising fractions of anthocyanin molecules separated from anthocyanin-containing vegetable and fruit juices and extracts. Anthocyanin fractions are separated at a select pH based on differences in polarity of the anthocyanin molecules in the anthocyanin-containing vegetable and fruit juices and extracts. The invention is directed to the anthocyanin fractions providing color characteristics similar to those provided by the synthetic blue colorant, FD&C Blue No. 1. The present invention is also directed to natural green colorants comprising the natural blue anthocyanin-containing colorant and a natural yellow colorant. The present invention is further directed to edible products comprising the natural blue anthocyanin-containing colorants.

IPC Classes  ?

• C09B 61/00 - Dyes of natural origin prepared from natural sources
• C07H 17/065 - Benzo[b]pyrans

Abstract

The present invention is directed to a method of isolating fractions of anthocyanin molecules from anthocyanin-containing vegetable and fruit juices and extracts, or combinations thereof, at a select pH based on differences in polarity of the anthocyanin molecules in the anthocyanin-containing vegetable and fruit juices and extracts.

IPC Classes  ?

• C09B 61/00 - Dyes of natural origin prepared from natural sources
• C07H 17/065 - Benzo[b]pyrans

Abstract

The present invention is directed to a method of isolating fractions of anthocyanin molecules from anthocyanin-containing vegetable and fruit juices and extracts, or combinations thereof, at a select pH based on differences in polarity of the anthocyanin molecules in the anthocyanin-containing vegetable and fruit juices and extracts.

IPC Classes  ?

• C09B 61/00 - Dyes of natural origin prepared from natural sources
• A23L 1/275 - Addition of dyes or pigments with or without optical brighteners
• C07H 17/065 - Benzo[b]pyrans

Abstract

The present invention is directed to natural blue anthocyanin-containing colorants comprising fractions of anthocyanin molecules separated from anthocyanin-containing vegetable and fruit juices and extracts. Anthocyanin fractions are separated at a select pH based on differences in polarity of the anthocyanin molecules in the anthocyanin-containing vegetable and fruit juices and extracts. The invention is directed to the anthocyanin fractions providing color characteristics similar to those provided by the synthetic blue colorant, FD&C Blue No. 1. The present invention is also directed to natural green colorants comprising the natural blue anthocyanin-containing colorant and a natural yellow colorant. The present invention is further directed to edible products comprising the natural blue anthocyanin-containing colorants.

IPC Classes  ?

• C09B 61/00 - Dyes of natural origin prepared from natural sources
• C07H 17/065 - Benzo[b]pyrans
• A23L 1/275 - Addition of dyes or pigments with or without optical brighteners

Abstract

Antiviral protease inhibitors, including peptidyl aldehydes, peptidyl α-ketoamides, peptidyl bisulfate salts, and peptidyl heterocycles, are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.

IPC Classes  ?

• A61K 38/06 - Tripeptides
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 207/27 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom

Abstract

The present invention relates to peptidomimetics for reactivating p53. Methods of using the peptidomimetics are also disclosed.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
• A61K 33/24 - Heavy metalsCompounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

An antenna structure comprising a dielectric substrate layer and a patch layer laminated on top of the dielectric substrate layer, wherein the antenna structure is adapted to provide dual band coverage by combining a patch mode and a slot mode configuration.

IPC Classes  ?

• H01Q 21/00 - Antenna arrays or systems
• H01Q 21/30 - Combinations of separate antenna units operating in different wavebands and connected to a common feeder system
• H01Q 9/04 - Resonant antennas
• H01Q 13/10 - Resonant slot antennas
• H01Q 5/364 - Creating multiple current paths

Abstract

The present invention relates to peptidomimetics for reactivating p53. Methods of using the peptidomimetics are also disclosed.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides

Abstract

4, and B are as defined herein).

IPC Classes  ?

• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to oligooxopiperazines for reactivating p53. Methods of using the oligooxopiperazines are also disclosed.

IPC Classes  ?

• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings

Abstract

A magnetic platform is provided and includes a patterned array of discrete magnetic elements positioned on a substrate, a plurality of first electromagnets for creating a first magnetic field substantially in the plane of the substrate, an electromagnetic coil for creating a second magnetic field substantially perpendicular to the plane of the substrate, and a control device for controlling the application of the magnetic fields. Processes for manipulating, transporting, separating and sorting micro-or nano-scale particles and biomolecules are also described.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

A metabolically engineered propionibacteria, genomically modified to express a bifunctional aldehyde/alcohol dehydrogenase identified as GenBank Gene ID: 6062148; GI: 170080868, having activity on propionyl-CoA, is prepared and used in a fermentative process to biosynthetically prepare n-propanol, propionic acid, or a combination thereof.

IPC Classes  ?

• C12P 7/04 - Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
• C07K 14/245 - Escherichia (G)
• C12P 7/52 - Propionic acidButyric acids

Abstract

A capsule configured for in vivo refilling of a therapeutic agent. In certain embodiments, the capsule may contain methotrexate.

IPC Classes  ?

• A61K 9/22 - Sustained or differential release type
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• A61M 5/142 - Pressure infusion, e.g. using pumps

Abstract

2, under partial vacuum, and combinations thereof.

IPC Classes  ?

• C01B 3/58 - Separation of hydrogen or hydrogen containing gases from gaseous mixtures, e.g. purification by contacting with solidsRegeneration of used solids including a catalytic reaction
• B01D 53/10 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with moving adsorbents with dispersed adsorbents
• C01B 3/34 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents
• C01B 3/48 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents followed by reaction of water vapour with carbon monoxide
• C10J 3/54 - Gasification of granular or pulverulent fuels by the Winkler technique, i.e. by fluidisation
• C10K 3/04 - Modifying the chemical composition of combustible gases containing carbon monoxide to produce an improved fuel, e.g. one of different calorific value, which may be free from carbon monoxide by catalytic treatment reducing the carbon monoxide content
• C10K 1/00 - Purifying combustible gases containing carbon monoxide
• B01D 53/62 - Carbon oxides

Abstract

Compositions and methods for treating post angioplasty restenosis, arteriosclerosis, and/or smooth muscle cell proliferation and/or neointimal hyperplasia in vascular tissues, and at least one composition of a redox based curcumin derivative, DAP-F(p) and a pharmaceutically acceptable carrier, are described.

IPC Classes  ?

• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof

Abstract

Methods and compositions for inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof, comprising administering an effective amount of an anti-miR-494 nucleic acid construct sufficient to target one or more tumor suppressor genes (TSGs) are described. Activation of the ERKl/2 pathway is a major determinant of diverse cellular processes and cancer development and is responsible for the transcription of several important miRNAs. Described herein is a link between the ERK1/2 pathway and BIM expression through miR-494. This ERK1/2 pathway regulates apoptosis and cell proliferation through miR-494 and mechanisms responsible for TRAIL resistance. Materials and methods related to the study and treatment of cancer are described.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Formulations for chemoprevention of oral cancer and precancerous lesions, and for methods for preparing the formulations are described.

IPC Classes  ?

• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/07 - Retinol compounds, e.g. vitamin A
• A61K 9/70 - Web, sheet or filament bases
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Abstract

A system for optimizing the use of network bandwidth by a mobile device including a mobile application client, which resides on the mobile device, and is connected to a cloud server, wherein the system analyzes user content consumption, provides a prefetching schedule to the mobile device, and the mobile device prefetches content partially in accordance with the schedule. A method of optimizing the use of network bandwidth using the system is also provided.

IPC Classes  ?

• H04W 28/02 - Traffic management, e.g. flow control or congestion control
• H04N 21/262 - Content or additional data distribution scheduling, e.g. sending additional data at off-peak times, updating software modules, calculating the carousel transmission frequency, delaying a video stream transmission or generating play-lists
• H04L 12/859 - Flow control actions based on the nature of the application, e.g. controlling web browsing or e-mail traffic

Abstract

The present invention discloses the discovery that miR-21 targets and down-regulates the core mismatch repair (MMR) recognition protein complex hMSH2 and hMSH6. Anti-sense miR-21 is therefore proven as therapeutic herein. Therefore, compositions, kits, therapies and other methods, including methods of treatment/amelioration of symptoms, are disclosed in the present invention.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A powertrain is adapted to drive ground-engaging elements disposed along longitudinally-opposing sides of a vehicle. The powertrain includes at least one engine, a first electric machine, a second electric machine, a third electric machine, a first differential mechanism and a second differential mechanism. The engine and first electric machine are operatively connected to the first and second differential mechanisms. The second electric machine is operatively connected to the first differential mechanism and the third electric machine is operatively connected to the second differential mechanism. The first and second differential mechanisms are each operatively connected to drivable engage one or more ground-engaging elements disposed on a different one of the longitudinally-opposing sides of the associated vehicle. A vehicle including such a powertrain as well as methods of using the same are also included.

IPC Classes  ?

• B60K 17/354 - Arrangement or mounting of transmissions in vehicles for driving both front and rear wheels, e.g. four wheel drive vehicles having separate mechanical assemblies for transmitting drive to the front or to the rear wheels or set of wheels
• B60K 6/42 - Arrangement or mounting of plural diverse prime-movers for mutual or common propulsion, e.g. hybrid propulsion systems comprising electric motors and internal combustion engines the prime-movers consisting of electric motors and internal combustion engines, e.g. HEVs characterised by the architecture of the hybrid electric vehicle
• B60K 6/387 - Actuated clutches, i.e. clutches engaged or disengaged by electric, hydraulic or mechanical actuating means

Abstract

Methods of treating bacterial infection by in a subject by administering a pharmaceutical composition including a celecoxib derivative are described. The compounds are particularly useful for treating infection by bacteria capable of growing inside macrophages, such as Myocobacteria tuberculosis.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• C07D 231/10 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members

Abstract

Disclosed are compositions comprising an engineered intein designed such that the self-cleaving activity of the intein can be modulated by a zinc-binding motif as well as methods and systems for making and using the compositions.

IPC Classes  ?

• C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells

Abstract

Methods for reducing blood clotting in a subject are provided, including methods to reduce the risk of and/or treat blot clotting pathologies, comprising administering a pharmaceutically-effective formulation of at least one isofonn of a tocotrienol to the subject. Also provided are compositions useful to reduce the risk or treat blood clotting pathologies, comprising one or more tocotrienol compounds.

IPC Classes  ?

• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• C07D 311/00 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
• C07D 311/02 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems

Abstract

A phased array antenna comprising a dielectric superstrate material, a ground plane material, a plurality of dipole structures located between the superstrate and ground plane materials, and a plurality of balun and matching networks in electrical communication with the plurality of dipole structures, wherein the phased array antenna is adapted to achieve a bandwidth of at least about 7:1.

IPC Classes  ?

• H01Q 1/24 - SupportsMounting means by structural association with other equipment or articles with receiving set
• H01Q 1/36 - Structural form of radiating elements, e.g. cone, spiral, umbrella
• H01Q 1/38 - Structural form of radiating elements, e.g. cone, spiral, umbrella formed by a conductive layer on an insulating support
• H01Q 21/26 - Turnstile or like antennas comprising arrangements of three or more elongated elements disposed radially and symmetrically in a horizontal plane about a common centre

Abstract

An antenna structure comprising a dielectric substrate layer and a patch layer laminated on top of the dielectric substrate layer, wherein the antenna structure is adapted to provide dual band coverage by combining a patch mode and a slot mode configuration. Exemplary embodiments of the present invention relate generally to a novel design for a compact, slot-loaded, proximity fed patch antenna structure. While the description herein describes frequency bands that are employed in global positioning system (GPS) implementations for exemplary calculations, the design may be equally applied to other applications where a compact, dual band antenna is desirable. Global navigation satellite systems (GNSS) such as GPS have become very commonly used devices.

IPC Classes  ?

• H01Q 21/28 - Combinations of substantially independent non-interacting antenna units or systems

Abstract

A phased array antenna comprising a dielectric superstrate material, a ground plane material, a plurality of dipole structures located between the superstrate and ground plane materials, and a plurality of balun and matching networks in electrical communication with the plurality of dipole structures, wherein the phased array antenna is adapted to achieve a bandwidth of at least about 7:1.

IPC Classes  ?

• H01Q 21/06 - Arrays of individually energised antenna units similarly polarised and spaced apart
• H01Q 21/00 - Antenna arrays or systems

Abstract

A facile method to produce covalently bonded graphene coating on various solid substrates is disclosed in the present invention. According to one embodiment, a combination of graphite, graphene oxide or graphene and silicon compound with or without a metal containing compound in an air free environment is processed at high temperatures to produce covalent carbide bonding among graphene layers and between graphene and substrate surface.

IPC Classes  ?

• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• C01B 31/04 - Graphite
• H01L 21/20 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth

Abstract

A method of (a) treating a lymphoproliferative disease in a subject in need thereof; (b) slowing the progression of lymphoproliferative disease in a subject who has been diagnosed with a lymphoproliferative disease; or (c) preventing or delaying development of a lymphoproliferative disease in a subject who is at risk of developing a lymphoproliferative disease. The method generally comprises administering to the individual an effective amount of a combination therapy comprising: i) at least one autophagy modulating agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof; and ii) at least one CDK inhibitor agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof, wherein the i) agent and the ii) agents are administered in amounts sufficient to enhance the cytotoxicity of the combination relative to the CDK inhibitor agent treatment alone.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 9/99 - Enzyme inactivation by chemical treatment
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

One embodiment includes a phase-based analog-to-digital converter (ADC) system. The system includes a voltage-to-phase converter configured to convert an input voltage to a phase difference corresponding to a phase-delay with respect to an input clock signal that is based on a magnitude of the input voltage. The system also includes a phase-to-digital converter configured to convert the phase difference into a digital output signal having a digital value corresponding to a magnitude of the phase difference.

IPC Classes  ?

• H03M 1/48 - Servo-type converters
• H03M 1/12 - Analogue/digital converters

Abstract

The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix Metalloproteinase-2 (MMP2); thereby promoting arteriogenesis.

IPC Classes  ?

• A61K 31/355 - Tocopherols, e.g. vitamin E

Abstract

The present invention provides methods to improve scar and burn outcome utilizing tocotrienols. In particular, various skin pathologies may be treated using the present methods. The present invention also provides methods to increase skin tissue concentrations of tocotrienols.

IPC Classes  ?

• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group

Abstract

This invention relates to compositions, systems, and methods for producing biofuels, such as butanol, and related compounds. More specifically, provided are methods of making recombinant microorganizms having non-naturally occurring metabolic pathways for the production of biofuels, and methods of producing biofuels using such organizms. Also provided are metabolically engineered microorganizms capable of producing butanol from a substrate.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• C12P 7/16 - Butanols
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

[00129] The disclosure also provides the biosynthetic machinery including isolated proteins, isolated polynucleotides, vectors, host cells, and methods for production of the antimicrobial agents described herein.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• A61P 31/04 - Antibacterial agents

Abstract

A method of inhibiting the growth of leukemic hematopoietic stem cells in a subject with leukemia is described. The method includes administering a therapeutically effective amount of a composition including a compound of formula I: I wherein R1 is independently selected from hydrogen and methyl; R2 is selected from the group consisting of 4,8-dimethyl-non-1-enyl, 4,8-dimethyl-nonyl, non-1-enyl, and nonanyl groups; X is a carboxyl, phosphonic, or sulfonic moiety, and n is an integer from 1 to 6, or a compound of Formula II: II wherein R1 is a C6-C12 alkyl or C6-C12 alkoxy group; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; and R3 is an alkyl or cycloalkyl group; or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/355 - Tocopherols, e.g. vitamin E

Abstract

Tertiary and quaternary amine-based cationic lipid nanoparticle formulations, peptides encapsulated therein, methods of making, and methods of using same are disclosed.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/14 - Particulate form, e.g. powders
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 35/00 - Antineoplastic agents